Company Analysis

Kyntra Bio, Inc. (KYNB)

Nasdaq: KYNB · Pharmaceutical Preparations · San Francisco, CA · filing with the SEC since 2002
Grade4.2
◀ Past 4.6● Present 4.1▶ Future 4.0
1 est.

Who runs Kyntra Bio, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Wettig Thane
CEO. First filing Jun 2020, latest Sep 9, 2026, 13 filings in all.
Officers reporting now
3
of 7 people with a filing in the last fifteen months
Directors reporting now
4
29 people on the record since 2014
Officerssales are open-market, Oct 6, 2025 to Oct 6, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Wettig ThaneCEOJun 2020Sep 9, 2026none
Delucia DavidChief Financial OfficerDec 2024Sep 9, 2026none
Schoeneck James AInterim PresidentNov 2014Jun 17, 2026none
Directorssales are open-market, Oct 6, 2025 to Oct 6, 2026
NameRoleFirst filingLatest filingSales, 12 months
Singer Andrew E.directorOct 2026Oct 6, 2026none
Edwards Jeffrey LdirectorOct 2015Jun 17, 2026none
Ho MaykindirectorDec 2018Jun 17, 2026none
Kauffman MichaeldirectorJun 2025Jun 17, 2026none
Earlier names on the record22, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton KYNB · research, not advice